The current health technology assessment (HTA) system in Australia has become increasingly cumbersome, resulting in longer delays in patient access to vital health technologies. Despite attempts to improve the system over the last two decades, the introduction of more processes and complex language has not alleviated suffering—rather, it has compounded it. Stakeholder agreements and legislative frameworks prioritizing cost over patient needs have led to a bureaucratic environment where patient input is often disregarded.
The recent HTA Review’s recommendations aim to streamline processes but risk perpetuating existing problems due to their reliance on vague definitions and non-transparent stakeholder selection. As timelines for access to medicines have steadily increased—from approximately 13.6 months in 2004 to potentially several years now—critics argue that without fundamental reform of the legal framework prioritizing price over patients, any new measures will likely fail to provide meaningful improvements for patient care.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pharmadispatch.com/news/why-is-the-system-slower-than-when-there-was-no-patient-involvement-of-input
